GM 102

Drug Profile

GM 102

Alternative Names: 3C23K; Anti-MISRII humanised monoclonal antibody 3C23K; GM102; Humanised monoclonal antibody 3C23K

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator LFB Biotechnologies
  • Developer GamaMabs Pharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Anti-Mullerian hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Gynaecological cancer

Most Recent Events

  • 26 Jul 2016 Phase-I clinical trials in Gynaecological cancer (Second-line therapy or greater, Late-stage disease) in Belgium (Parenteral)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top